Gubin, M. M., Artyomov, M. N., Mardis, E. R. & Schreiber, R. D. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J. Clin. Invest. 125, 3413–3421 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 18, 1009–1021 (2017).

Article  CAS  PubMed  Google Scholar 

Yarchoan, M., Johnson, B. A. III, Lutz, E. R., Laheru, D. A. & Jaffee, E. M. Targeting neoantigens to augment antitumour immunity. Nat. Rev. Cancer 17, 209–222 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang, H., Zhong, Y., Peng, C., Chen, J. Q. & Tian, D. Important role of indels in somatic mutations of human cancer genes. BMC Med. Genet. 11, 128 (2010).

Article  PubMed  PubMed Central  Google Scholar 

Smith, C. C. et al. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J. Clin. Invest. 128, 4804–4820 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209–249 (2021).

Article  PubMed  Google Scholar 

Cancer Genome Atlas Research, N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).

Article  Google Scholar 

Ricketts, C. J. et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 23, 313–326 e315 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Latif, F. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317–1320 (1993).

Article  CAS  PubMed  Google Scholar 

Clark, P. E. & Cookson, M. S. The von Hippel-Lindau gene: turning discovery into therapy. Cancer 113, 1768–1778 (2008).

Article  CAS  PubMed  Google Scholar 

Choueiri, T. K. & Motzer, R. J. Systemic therapy for metastatic renal-cell carcinoma. N. Engl. J. Med. 376, 354–366 (2017).

Article  CAS  PubMed  Google Scholar 

Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225–233 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bruni, D., Angell, H. K. & Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer 20, 662–680 (2020).

Article  CAS  PubMed  Google Scholar 

Senbabaoglu, Y. et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 17, 231 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).

Article  PubMed  Google Scholar 

Hsieh, J. J. et al. Renal cell carcinoma. Nat. Rev. Dis. Prim. 3, 17009 (2017).

Article  PubMed  Google Scholar 

Mitchell, T. J. et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell 173, 611–623.e17 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 173, 581–594.e12 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Siska, P. J. et al. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI Insight https://doi.org/10.1172/jci.insight.93411 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Giraldo, N. A. et al. Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin. Cancer Res. 23, 4416–4428 (2017).

Article  CAS  PubMed  Google Scholar 

Barata, P. C. & Rini, B. I. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J. Clin. 67, 507–524 (2017).

Article  PubMed  Google Scholar 

Beckermann, K. E. et al. CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation. JCI Insight https://doi.org/10.1172/jci.insight.138729 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Chevrier, S. et al. An immune atlas of clear cell renal cell carcinoma. Cell 169, 736–749.e718 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borcherding, N. et al. Mapping the immune environment in clear cell renal carcinoma by single-cell genomics. Commun. Biol. 4, 122 (2021). 

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cole, W. H. & Everson, T. C. Spontaneous regression of cancer: preliminary report. Ann. Surg. 144, 366–383 (1956).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer, R. J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530–2540 (1999).

Article  CAS  PubMed  Google Scholar 

Hartmann, J. T. & Bokemeyer, C. Chemotherapy for renal cell carcinoma. Anticancer. Res. 19, 1541–1543 (1999).

CAS  PubMed  Google Scholar 

Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).

Article  CAS  PubMed  Google Scholar 

Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141–151 (1999).

Article  CAS  PubMed  Google Scholar 

Hansen, U. K. et al. Tumor-infiltrating T cells from clear cell renal cell carcinoma patients recognize neoepitopes derived from point and frameshift mutations. Front. Immunol. 11, 373 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Litchfield, K. et al. Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. Nat. Commun. 11, 3800 (2020). 

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 20, 1370–1385 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103–1115 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marcus, L. et al. FDA Approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin. Cancer Res. 27, 4685–4689 (2021).

Article  CAS  PubMed  PubMed Central